Snovitra is a prescription medication formulated with Vardenafil, a potent phosphodiesterase type 5 (PDE5) inhibitor, designed to address the physiological mechanisms of erectile dysfunction. It functions by enhancing blood flow to the penile cavernosal bodies upon sexual stimulation, facilitating the achievement and maintenance of an erection sufficient for satisfactory sexual activity. This medication is distinguished by its reliable pharmacokinetic profile, offering a predictable therapeutic window for planned intimacy. It is intended for adult males experiencing vasculogenic erectile dysfunction and should be used under appropriate medical supervision following a comprehensive clinical assessment to ensure suitability and safety.

Features

• Active Pharmaceutical Ingredient: Vardenafil (as Vardenafil Hydrochloride Trihydrate)
• Available dosage strengths: 10 mg, 20 mg, 40 mg film-coated tablets
• Rapid onset of action, typically within 25-60 minutes post-administration
• Duration of therapeutic effect extends for up to 4-5 hours
• High selectivity for phosphodiesterase type 5 (PDE5) enzyme
• Formulated for oral administration with or without food (though high-fat meals may delay absorption)

Benefits

• Facilitates the achievement of firm, reliable erections when sexually aroused.
• Supports spontaneous sexual activity within the medication’s effective window.
• Enhances overall sexual confidence and reduces performance-related anxiety.
• Improves satisfaction for both the individual and their partner.
• Offers dosing flexibility with multiple strengths to tailor therapy to individual response and tolerability.
• Provides a well-established efficacy and safety profile backed by clinical data.

Common use

Snovitra is clinically indicated for the treatment of erectile dysfunction (ED) in adult males. Erectile dysfunction is characterized by the consistent or recurrent inability to attain and/or maintain a penile erection sufficient for satisfactory sexual performance. The pathophysiology often involves inadequate relaxation of cavernosal smooth muscle and impaired arterial inflow, which Vardenafil addresses through selective PDE5 inhibition. It is not indicated for use in women, children, or adolescents. It does not protect against sexually transmitted diseases and is not a form of hormonal therapy or aphrodisiac.

Dosage and direction

The recommended starting dose for most patients is 10 mg, taken orally approximately 25-60 minutes prior to anticipated sexual activity. The dosage may be titrated based on efficacy and tolerability to a maximum recommended dose of 20 mg per 24-hour period. For patients with specific considerations (e.g., hepatic impairment, concomitant use of certain medications), a lower starting dose of 5 mg may be advised. The tablet should be swallowed whole with a glass of water; it can be taken with or without food, though consumption with a high-fat meal may delay the time to onset of effect. Sexual stimulation is required for the medication to be effective. Do not exceed one dose in a 24-hour period.

Precautions

Prior to initiating therapy with Snovitra, a thorough medical evaluation should be conducted to diagnose erectile dysfunction, identify underlying causes, and assess cardiovascular health, as sexual activity carries a potential cardiac risk. Use with caution in patients with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie’s disease), conditions predisposing to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia), or bleeding disorders. Caution is advised in patients with severe hepatic impairment (Child-Pugh C), severe renal impairment (creatinine clearance <30 mL/min), or hypotension. This medication may cause dizziness and visual disturbances; patients should be cautioned about driving or operating machinery until they know how the drug affects them. It is not intended for chronic daily dosing.

Contraindications

Snovitra is contraindicated in patients with a known hypersensitivity to Vardenafil or any of the excipients in the formulation. Its concurrent administration with any form of organic nitrate therapy (e.g., nitroglycerin, isosorbide mononitrate or dinitrate) or nitric oxide donors (e.g., amyl nitrite) is strictly prohibited due to the risk of profound hypotension, syncope, myocardial infarction, or stroke. It is also contraindicated in patients who have loss of vision in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this event was related to previous PDE5 inhibitor exposure. Concomitant use with guanylate cyclase stimulators, such as riociguat, is contraindicated.

Possible side effect

Like all pharmaceuticals, Snovitra can cause side effects, although not everybody gets them. Commonly reported adverse reactions (≥1/100 to <1/10) are headache, flushing, nasal congestion, dyspepsia, and dizziness. Uncommon side effects (≥1/1,000 to <1/100) include visual disturbances (e.g., blurred vision, cyanopsia), palpitations, tachycardia, hypotension, nausea, and back pain or myalgia. Rarely (≥1/10,000 to <1/1,000), priapism (a prolonged and painful erection lasting more than 4 hours), syncope, sudden decrease or loss of hearing, and non-arteritic anterior ischemic optic neuropathy (NAION) have been reported. If an erection lasts longer than 4 hours, seek immediate medical attention to avoid potential long-term tissue damage.

Drug interaction

Snovitra can potentiate the hypotensive effect of alpha-blockers (e.g., doxazosin, tamsulosin); concomitant use is not recommended, and if necessary, should only be initiated under close medical supervision. As stated, concurrent use with nitrates is absolutely contraindicated. Vardenafil is primarily metabolized by the cytochrome P450 3A4 enzyme. Therefore, co-administration with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, indinavir, clarithromycin) will significantly increase Vardenafil plasma concentrations; a maximum dose of 5 mg Snovitra in a 24-hour period is recommended in such cases. Moderate CYP3A4 inhibitors (e.g., erythromycin, aprepitant, fluconazole) may also increase exposure; caution is advised. Inducers of CYP3A4 (e.g., rifampicin, phenobarbital, phenytoin, carbamazepine, St. John’s Wort) may reduce Vardenafil efficacy.

Missed dose

Snovitra is not intended for scheduled daily administration; it is taken on an as-needed basis prior to sexual activity. Therefore, the concept of a “missed dose” does not apply. Do not take an extra dose to make up for a missed opportunity. Adhere to the dosing schedule of one tablet per planned sexual encounter, with a minimum of 24 hours between doses.

Overdose

In the event of overdose, standard supportive measures should be employed. Given the vasodilatory effects of Vardenafil, the primary expected manifestations would be related to its cardiovascular actions, including severe hypotension, syncope, and potentially reflex tachycardia. Management should include placing the patient in the supine position with the legs elevated to restore blood pressure and ensure adequate fluid intake. Hemodialysis is not expected to accelerate clearance as Vardenafil is highly protein-bound and extensively metabolized. Active management of severe, persistent hypotension may require IV fluid administration and, if necessary, vasopressor therapy (epinephrine is not recommended; consider norepinephrine). Standard medical support for any presenting symptoms should be provided.

Storage

Store Snovitra tablets in the original blister packaging at room temperature (15°C to 30°C or 59°F to 86°F). Protect from light and moisture. Keep the medication out of the sight and reach of children and pets. Do not use the medicine after the expiration date printed on the packaging. Do not dispose of medications via wastewater or household waste; consult your pharmacist for proper disposal methods to avoid environmental contamination.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on the typical properties of the drug and may not cover all possible uses, directions, precautions, interactions, or adverse effects.

Reviews

“After discussing options with my urologist, we decided on Snovitra. The effect is predictable and has significantly improved my quality of life. I experienced mild flushing initially, but it subsided.” – M.C., 54 “The 20mg dose provides the efficacy I need with a rapid onset. It has restored normality to my relationship. I appreciate the clear guidance from my doctor on timing and food interactions.” – A.B., 61 “As a healthcare professional, I value its specific mechanism of action and well-documented profile. It has worked effectively for me with minimal side effects (slight nasal congestion).” – Dr. K.L., 48 “I was initially apprehensive, but the results have been consistent and reliable. It’s important to follow the dosing instructions precisely for the best experience.” – R.S., 57